Natixis bought a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 19,600 shares of the company's stock, valued at approximately $522,000. Natixis owned 0.07% of Castle Biosciences as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently made changes to their positions in the stock. Barclays PLC grew its holdings in shares of Castle Biosciences by 310.7% in the 3rd quarter. Barclays PLC now owns 52,301 shares of the company's stock valued at $1,491,000 after buying an additional 39,567 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Castle Biosciences by 165.2% in the third quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company's stock worth $1,980,000 after acquiring an additional 43,241 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Castle Biosciences by 1.1% in the third quarter. Geode Capital Management LLC now owns 624,683 shares of the company's stock worth $17,820,000 after acquiring an additional 7,004 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Castle Biosciences by 2.7% during the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company's stock worth $43,879,000 after purchasing an additional 40,377 shares during the period. Finally, Truist Financial Corp lifted its holdings in shares of Castle Biosciences by 4.6% during the 4th quarter. Truist Financial Corp now owns 21,303 shares of the company's stock valued at $568,000 after purchasing an additional 928 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.
Castle Biosciences Stock Up 1.0 %
Shares of NASDAQ:CSTL traded up $0.20 during trading on Wednesday, hitting $20.05. 394,176 shares of the company were exchanged, compared to its average volume of 390,992. The stock has a market cap of $578.34 million, a price-to-earnings ratio of 100.26 and a beta of 1.11. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a fifty-two week low of $16.97 and a fifty-two week high of $35.84. The firm has a fifty day moving average price of $20.66 and a two-hundred day moving average price of $26.39.
Insider Buying and Selling
In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total value of $221,613.39. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Derek J. Maetzold sold 2,130 shares of Castle Biosciences stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $19.52, for a total value of $41,577.60. Following the transaction, the insider now owns 78,335 shares of the company's stock, valued at $1,529,099.20. This represents a 2.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,321 shares of company stock worth $774,644. Insiders own 7.20% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the stock. Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the company a "buy" rating in a research note on Friday, March 28th. Stephens reaffirmed an "overweight" rating and issued a $41.00 target price on shares of Castle Biosciences in a research note on Thursday, January 2nd. Finally, Robert W. Baird increased their target price on Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $38.75.
Get Our Latest Stock Report on CSTL
Castle Biosciences Company Profile
(
Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Further Reading
Before you consider Castle Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.
While Castle Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
